LAUSR

1 Mori K, Mostafaei H, Sari Motlagh R et al. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. BJU Int. 2021; https://doi.org/10.1111/bju.15507. 2 Kyriakopoulos CE, Chen Y-H, Carducci MA et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 2018; 36: 1080–7. 3 Fizazi K, Tran NamPhuong, Fein L et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019; 20: 686–700. 4 Sathianathen NJ, Koschel S, Thangasamy IA et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur. Urol. 2020; 77: 365–72. 5 Wang L, Paller CJ, Hong H, De Felice A, Alexander GC, Brawley O. Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis. JAMA Oncol. 2021; 7: 412–20. 6 Takahara K, Naiki T, Ito T et al. Useful predictors of progression-free survival for Japanese patients with LATITUDE-high-risk metastatic castration-sensitive prostate cancer who received upfront abiraterone acetate. Int. J. Urol. 2022; 29: 229–34.